Therapeutic cancer targeting peptides
Olulanu H Aina1, Thomas C Sroka, Man-Ling Chen
1Univeristy of California Davis Cancer Center, Division of Hematology/Oncology, and Department of Internal Medicine, University of California Davis, 4501 X Street, Sacramento 95817, USA.
Abstract:
Antitumor monoclonal antibodies have shown clinical promise as cancer cell surface targeting agents. More tumor targeting antibodies are likely to be approved by the FDA in the next few years. However, there are two major limitations in antibody-targeted therapy: large size and nonspecific uptake of the antibody molecules by the liver and the reticuloendothelial system. These result in poor tumor penetration of antibody pharmaceuticals and dose-limiting toxicity to the liver and bone marrow. Peptides are excellent alternative targeting agents for human cancers, and they may alleviate some of the problems with antibody targeting. In the last decade, several investigators have successfully used combinatorial library methods to discover cell surface binding peptides that may be useful for cancer targeting. The phage-display library technique and the "one-bead one-compound" combinatorial library method are the two approaches that have been used. Cancer cell surface receptors or endothelial cell surface receptors of the neovasculature are the two popular therapeutic targets for cancer. Results from preclinical studies with some peptides are encouraging in their targeting potential.
Insights
Peptides offer a promising alternative to large monoclonal antibodies for cancer targeting. These smaller molecules show potential for improved tumor penetration and reduced toxicity in preclinical studies.
Area of Science:
- Oncology
- Biotechnology
- Pharmaceutical Sciences
Background:
- Monoclonal antibodies show promise for cancer cell surface targeting but face limitations.
- Large antibody size and non-specific liver uptake hinder tumor penetration and cause toxicity.
- Alternative targeting agents are needed to overcome current antibody-based therapy challenges.
Purpose of the Study:
- To explore peptides as alternative cancer targeting agents.
- To address limitations associated with antibody-based cancer therapies.
- To evaluate the potential of peptide-based targeting for improved cancer treatment.
Main Methods:
- Utilizing combinatorial library methods to discover cell surface binding peptides.
- Employing phage-display library techniques and the "one-bead one-compound" method.
- Focusing on targeting cancer cell surface receptors and tumor neovasculature endothelial receptors.
Main Results:
- Preclinical studies demonstrate encouraging results for peptide-based cancer targeting.
- Peptides show potential to overcome the size and non-specific uptake limitations of antibodies.
- Identified peptides exhibit potential for targeting cancer cell surface receptors.
Conclusions:
- Peptides represent a viable alternative to monoclonal antibodies for cancer targeting.
- Peptide-based strategies may improve tumor penetration and reduce dose-limiting toxicities.
- Further research into peptide targeting agents holds promise for advancing cancer therapy.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:27Tumor Immunotherapy